Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - Антинеопластични средства - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - псориазис - Имуносупресори - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Антинеопластични средства - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - Препарати против затлъстяване, с изключение на тези, диетични продукти - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - Паркинсонова болест - Антипаркинсонови лекарства - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - Множествена Склероза, Рецидивно-Ремиттирующее - Имуносупресори - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - Други дерматологични препарати - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - Дерматит, Атопич - Други дерматологични препарати - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Bulgaria - Bulgaria - Adama

adama - Емулсионен концентрат (ЕК) - 100 г/л тебуконазол + 150 г/л фенпропидин + 200 г/л прохлораз - Фунгициди

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

Сева Анимал Хелт България ЕООД - Вирус е инфекциозно бурсальной болест (ibdv), аттенуированные, прецедете syza26 - концентрат и разтворител за инжекционна суспензия - 2.65 - 4.2 log10cid50 - пилета